Vimarsana
Biggest News Aggregation in the World

Page 2 - Genetics Service News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetics Service. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetics Service Today - Breaking & Trending Today

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium - Vimarsana News

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium,...

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting - Vimarsana News

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking...

Passage Bio Presents New Interim Clinical Data for Patients - Vimarsana News

Passage Bio Presents New Interim Clinical Data for Patients

Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study...

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022 - Vimarsana News

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

/PRNewswire/ -- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Dose-dependent...

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022 - Vimarsana News

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

/PRNewswire/ -- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Dose-dependent...